Log ind
Genmab has reinforced foundation with ASH data

Genmab’s bone marrow cancer treatment has delivered the goods with fresh data presented at a hematology conference in San Diego. It reinforces the drug’s position in the market and the entire future foundation for the Danish biotech company, says an analyst.

Novo’s science chief says he is not letting go of the Holy Grail

Although Novo Nordisk has discontinued its activities in what CSO Mads Krogsgaard Thomsen has previously called the Holy Grail of diabetes care, he is not resigned to letting go completely. A partnership with the world’s most cited researcher could bring Novo back in the game. But for now, he has turned his attention to another Holy Grail.

ANNONCE


ANNONCE